6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
13m ago	Creating America’s First Transcontinental Railroad: Union Pacific and Norfolk Southern’s Amended STB Merger Application Estimates Shippers Will Save $3.5 Billion Annually
13m ago	Marcus Corporation Reports First Quarter Fiscal 2026 Results
13m ago	Intercontinental Exchange Approves Second Quarter Dividend of $0.52 per Share
13m ago	Lincoln Electric Reports First Quarter 2026 Results
14m ago	Dragonfly Energy to Report First Quarter 2026 Financial and Operational Results on May 14, 2026

About

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) — investor relations, events, news, and company updates on 6ix.

Latest News

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Financials

Revenue

$123.67 M

Market Cap

$1.37 B

EPS

-0.46

Community Chat

Ask AI